Switching From Arixtra (Fondaparinux) to Angiomax (Bivalirudin) or Unfractionated Heparin in Patients With Acute Coronary Syndromes (ACS) Without ST-segment Elevation Undergoing Percutaneous Coronary Intervention (PCI): SWITCH III
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 100
- 试验地点
- 7
- 主要终点
- The Primary Endpoint Will be in Hospital Major Bleed as Defined by the Study Protocol, Assessed at Three Time Points: After Study Drug Administration, But Prior to Randomization;After Randomization During PCI; and After PCI, Prior to Discharge
研究概览
简要总结
The primary objective of this clinical trial is to evaluate safety of switching from fondaparinux to either unfractionated heparin or bivalirudin for patients experiencing acute coronary syndrome undergoing percutaneous coronary angioplasty.
详细描述
This is a prospective open label, randomized, multi-center registry. One hundred patients who received fondaparinux within the 24 hours prior to presentation to the coronary catheterization lab and who are suitable for percutaneous coronary intervention. The patients will be randomized in a 1:1 fashion to either unfractionated heparin or bivalirudin during the angioplasty. All patients will be followed throughout the duration of the hospital stay.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The patient is, male or female, > 18 years of age;
- •The patient presents with coronary syndrome, unstable angina or non ST segment elevated myocardial infarction (NSTEMI) defined as at least one of the following criteria:
- •Elevated creatine kinase MB or Troponin I or T (above ULN)
- •ECG changes indicative of ischemia
- •The patient is scheduled for angiography, with possible angioplasty, evaluation of their coronary disease;
- •The patient is able and willing to conform to the requirements of the study and voluntarily signs an Informed Consent.
- •ST elevated myocardial infarction within the preceding 48 hours;
- •Patient weighs more than 400 lbs (181.2 kg) or less than 110 lbs (50 kg);
- •Patients presenting on or received bivalirudin, GP IIb/IIIa inhibitors or low-molecular weight heparin within the preceding 24 hours;
- •Patients that received unfractionated heparin less than or equal to 90 minutes prior to fondaparinux administration.
- •Patients with known conditions of bleeding diathesis or actively bleeding within the previous 6 months (GI bleed etc.);
- •Known diagnosis of acute bacterial endocarditis;
- •Patients with cardiogenic shock or required intra-aortic balloon pump (IABP)
- •If patient is on warfarin (Coumadin) therapy;
- •Patients who had a major or minor stroke (CVA or TIA) or major surgery within the past 6 months;
- •Known impaired renal function (creatinine ≥ 3.0 mg/dL (265.2 μmol/L),) status post renal transplant, patients on chronic dialysis or creatinine clearance ≤ 30 ml/min;
- •A platelet count of less than 100,000 cells/mm3;
- •Known allergies to fondaparinux, aspirin, clopidogrel bisulfate (PlavixR), ticlopidine (TiclidR), heparin, bivalirudin, or contrast that cannot be medically managed;
- •Prior angioplasty within the previous 30 days;
- •Contraindication to low-molecular weight heparin, unfractionated heparin or bivalirudin;
- •Pregnant or lactating women;
- •Any significant medical condition, which in the investigator's opinion, may interfere with the patient's optimal participation in the study;
- •Currently participating in an investigational drug or another device study.
排除标准
- 未提供
研究组 & 干预措施
Heparin
Patients are switched from fondaparinux to heparin, receiving a dose of 60 U/Kg IV during the PCI
干预措施: Switching from Fondaparinux to Bivalirudin or Unfractionated Heparin (Drug)
Bivalirudin
Patients switched from fondaparinux to bivalirudin, received a bolus of 0.75 mg/kg IV followed by infusion of 1.75 mg/g per hour infusion during the PCI.
干预措施: Switching from Fondaparinux to Bivalirudin or Unfractionated Heparin (Drug)
结局指标
主要结局
The Primary Endpoint Will be in Hospital Major Bleed as Defined by the Study Protocol, Assessed at Three Time Points: After Study Drug Administration, But Prior to Randomization;After Randomization During PCI; and After PCI, Prior to Discharge
时间窗: During hospitalization, after PCI
Characterized as fatal bleed, major bleed (SWITCH III criteria) or major bleed (OASIS criteria)
次要结局
- Secondary in Hospital Endpoint Will be In-hospital Death (Non-hemorrhagic Related), Vascular Access Site Complications, Myocardial Infarction, Need for Repeat Revascularization, Procedural Complication and Catheter Thrombosis(during index hospitalization)